GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surgalign Holdings Inc (OTCPK:SRGAQ) » Definitions » EBITDA per Share

Surgalign Holdings (Surgalign Holdings) EBITDA per Share : $-7.23 (TTM As of Mar. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Surgalign Holdings EBITDA per Share?

Surgalign Holdings's EBITDA per Share for the three months ended in Mar. 2023 was $0.38. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-7.23.

During the past 3 years, the average EBITDA per Share Growth Rate was -135.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Surgalign Holdings's EBITDA per Share or its related term are showing as below:

SRGAQ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -231.2   Med: 3.2   Max: 49.7
Current: -135.8

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Surgalign Holdings was 49.70% per year. The lowest was -231.20% per year. And the median was 3.20% per year.

SRGAQ's 3-Year EBITDA Growth Rate is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 8.1 vs SRGAQ: -135.80

Surgalign Holdings's EBITDA for the three months ended in Mar. 2023 was $5.03 Mil.

During the past 3 years, the average EBITDA Growth Rate was -7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Surgalign Holdings was 49.30% per year. The lowest was -157.40% per year. And the median was 4.10% per year.


Surgalign Holdings EBITDA per Share Historical Data

The historical data trend for Surgalign Holdings's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surgalign Holdings EBITDA per Share Chart

Surgalign Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.70 -19.21 -29.05 -29.69 -8.00

Surgalign Holdings Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 -0.71 -1.33 -5.56 0.38

Surgalign Holdings EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Surgalign Holdings's EBITDA per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA per Share(A: Dec. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=-52.456/6.555
=-8.00

Surgalign Holdings's EBITDA per Share for the quarter that ended in Mar. 2023 is calculated as

EBITDA per Share(Q: Mar. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=5.029/13.320
=0.38

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surgalign Holdings  (OTCPK:SRGAQ) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Surgalign Holdings EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Surgalign Holdings's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Surgalign Holdings (Surgalign Holdings) Business Description

Traded in Other Exchanges
N/A
Address
520 Lake Cook Road, Suite 315, Deerfield, IL, USA, 60015
Surgalign Holdings Inc is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company continues to invest in clinically validated innovation to deliver the Best surgical outcomes and improve patient's lives. It markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. The U.S. market accounts for the vast majority of revenue. It has commercial and design centers in San Diego, California, and Wurmlingen, Germany.
Executives
Elizabeth A. Lapuma director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Jill Kathleen Frizzley director P.O. BOX 1541, ONE BLUE HILL PLAZA, PEARL RIVER NY 10965
Paolo Amoruso officer: Chief Legal Officer C/O HYPERDYNAMICS CORPORATION, 12012 WICKCHESTER LANE, SUITE 475, HOUSTON TX 77079
David Lyle officer: Chief Financial Officer 6290 SEQUENCE DRIVE, SAN DIEGO CA 92121
Marc E. Mackey officer: EVP, Digital Surgery 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Terry M. Rich officer: President, Global Spine 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
William Scott Durall officer: Chief Commercial Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Christopher Thunander officer: Chief Accounting Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Thomas Mceachin director 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Nicholas J Valeriani director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Enrico Sangiorgio officer: EVP, International 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Stuart F. Simpson director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Pawel Lewicki director 296 WOODWARD BLVD., TULSA OK 74114
Jeffrey C Lightcap director 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019

Surgalign Holdings (Surgalign Holdings) Headlines